Hourigan Christopher S, Karp Judith E
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, 1650 Orleans Street, Baltimore, MD 21231-1000, USA.
Curr Opin Investig Drugs. 2010 Jun;11(6):669-77.
Acute myelogenous leukemia (AML) is a disease more common in older patients than in the young. It is increasingly recognized that conventional cytotoxic chemotherapies used in children and young adults may not be appropriate in older adults because of diverse host- and disease-biology factors. This review highlights some of the most promising new treatment options that are being evaluated for older patients with AML. These options include CPX-351 (Celator Pharmaceuticals Inc), a unique liposomal formulation of a fixed ratio of cytarabine and daunorubicin; timed sequential therapy with the CDK inhibitor alvocidib (flavopiridol; sanofi-aventis/NCI); the second-generation purine nucleoside analog clofarabine; the farnesyltransferase inhibitor tipifarnib (Johnson & Johnson Pharmaceutical Research and Development LLC); and the DNA methyltransferase inhibitors decitabine and azacitidine.
急性髓系白血病（AML）在老年患者中比在年轻患者中更常见。人们越来越认识到，由于多种宿主和疾病生物学因素，儿童和年轻成人使用的传统细胞毒性化疗方法可能不适用于老年人。本综述重点介绍了一些正在为老年AML患者评估的最有前景的新治疗选择。这些选择包括CPX-351（Celator制药公司），一种阿糖胞苷和柔红霉素固定比例的独特脂质体制剂；使用细胞周期蛋白依赖性激酶（CDK）抑制剂阿沃西地布（黄酮哌啶醇；赛诺菲-安万特/美国国立癌症研究所）的定时序贯疗法；第二代嘌呤核苷类似物氯法拉滨；法尼基转移酶抑制剂替匹法尼（强生制药研发有限责任公司）；以及DNA甲基转移酶抑制剂地西他滨和阿扎胞苷。
